Related Experiment Video
Updated: Jun 4, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
R W F van Leeuwen1, E L Swart, E Boven
1Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands.
Summary
Potential drug interactions (PDIs) are common in cancer patients receiving intravenous treatment, affecting treatment efficacy and safety. Routine screening before chemotherapy is recommended to mitigate risks.
Area of Science:
- Oncology
- Pharmacology
- Clinical Pharmacy
Background:
- Drug interactions in cancer patients can worsen adverse events or decrease treatment effectiveness.
- Assessing the prevalence of potential drug interactions (PDIs) in ambulatory cancer patients receiving intravenous therapy is crucial.
Purpose of the Study:
- To determine the prevalence of PDIs in ambulatory cancer patients undergoing intravenous treatment.
- To identify risk factors associated with PDIs in this patient population.
Main Methods:
- Data collection involved structured interviews and medical chart reviews for anticancer drugs, over-the-counter (OTC) medications, and comorbidities.
- PDIs were identified using both electronic screening software and manual review of peer-reviewed literature.
Main Results:
- Out of 278 enrolled patients, 161 (58%) experienced at least one PDI, with 348 PDIs identified overall.
- Major (34%) and moderate (60%) interactions were common, frequently involving coumarins, quinolones, antiepileptics, and hydrochlorothiazide.
- Increased drug count (OR=1.4) and OTC drug use (OR=0.56) were identified as risk factors.
Conclusions:
- Potential drug interactions are highly prevalent in patients with hematological or oncological diseases.
- Routine screening for PDIs should be implemented prior to chemotherapy administration to enhance patient safety and treatment outcomes.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...